Zymeworks' zanidatamab-hrii gains FDA approval for first-line HER2+ gastroesophageal cancer

Zymeworks announced the FDA approved a Ziihera plus tislelizumab and chemotherapy regimen for first-line HER2-positive gastroesophageal adenocarcinoma, boosting its diversified collaboration strategy.